TRENDING :  Market Movers  |  Top 50   SPY (0.74%)    JNJ (-0.37%)    TSLA (0.99%)    UGAZ (-13.3%)    RLGT (0.9%)    RDFN (-0.27%)    OMER (1.74%)    NVDA (-0.37%)    NNDM (2.34%)    KOPN (1.09%)    HTZ (1.77%)    HTGM (8.07%)    GS (1.07%)    GNC (0.58%)    GDX (1.45%)    FB (-0.1%)    EWC (1.11%)    DSLV (-3.59%)    CI (0.31%)    CARA (2.98%)    BUZ (0%)    BOIL (-7.98%)    BHC (-0.4%)    AU (1.73%)    ASNA (-2.94%)

 ALXN - Alexion Pharmaceuticals

$107.16 (1.1%)

Next Earnings



Analyst Rating

CompanyAnalyst NamePT ActionActionRatingTargetDate
CitigroupRobyn KarnauskasLowersMaintainsBuy$190.0010/25/18
Morgan StanleyMatthew HarrisonRaisesMaintainsOverweight$165.0010/11/18
Stifel NicolausStephen WilleyRaisesMaintainsHold$136.0009/25/18
Stifel NicolausStephen WilleyLowersDowngradesHold$130.0008/07/18
JP MorganAnupam RamaRaisesMaintainsOverweight$188.0007/27/18
Credit SuisseAlethia YoungRaisesMaintainsOutperform$154.0006/05/18
CitigroupRobyn KarnauskasRaisesMaintainsBuy$173.0004/30/18
Stifel NicolausStephen WilleyRaisesMaintainsBuy$155.0004/27/18
NomuraChristopher MaraiRaisesMaintainsBuy$156.0003/19/18
Credit SuisseAlethia YoungRaisesMaintainsOutperform$149.0003/16/18
CitigroupRobyn KarnauskasLowersMaintainsBuy$170.0002/09/18
Credit SuisseAlethia YoungAnnouncesAssumesOutperform$147.0001/18/18
Raymond JamesDowngradesOutperform$0.0001/04/18


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.



AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals

AMAG Pharmaceuticals Inc AMAG has entered into an agreement to acquire Connecticut based privately held Perosphere Pharmaceuticals Inc which will add the latter s investigational candidate ciraparantag to its portfolio This move will strengthen the company s expertise in

The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

For Immediate Release Chicago IL December 12 2018 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog

Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher

Abeona Therapeutics Inc ABEO was a big mover last session as the company saw its shares rise more than 5 on the day The move came on solid volume too with far more shares changing hands than in a normal session The stock picked up sharply from the near flat trend of 7 50 to 8 50 in

4 Biotech Stocks Investors Can Add to Their Portfolio in 2019

It has been a disappointing year for the biotech industry The NASDAQ Biotechnology Index NBI has lost 5 so far in 2018 While the year started on a choppy note things were steady in the middle of the year However the industry lost momentum in the last two months The performance

Here's Why Ra Pharmaceuticals Inc. Is Soaring Today

What happened Shares of Ra Pharmaceuticals Inc NASDAQ RARX 160 a clinical stage biopharmaceutical company are on the rise after its lead candidate hit the mark in a mid stage study for the treatment of myasthenia gravis The stock climbed 20 3 before settling back to a 9

5 Top Drug/Biotech Merger & Acquisition Targets for 2019

As far as M amp A activity in the biotech drug sector is concerned 2018 started with a bang with expectations of record breaking activity in the year The new tax reforms left more cash in the hands of drug biotech companies that could be invested for M amp A activity The first few months

Clovis Oncology (CLVS) in Focus: Stock Moves 6.9% Higher

Clovis Oncology Inc CLVS was a big mover last session as the company saw its shares rise nearly 7 on the day The move came on solid volume too with far more shares changing hands than in a normal session This continues the recent uptrend for the company as the stock is now up 46 7 in

Biogen (BIIB) In-Licenses ALS Candidate BIIB067 From Ionis

Biogen Inc BIIB announced that it has obtained a worldwide license to develop and commercialize Ionis Pharmaceuticals IONS pipeline candidate BIIB067 IONIS SOD1RX This will enable the company to exercise an option per the deal it inked with Ionis in April 160 160 In April

Inovio (INO) to Receive Milestone Payment From AstraZeneca

Inovio Pharmaceuticals Inc INO announced that it will receive an undisclosed amount of milestone payment from AstraZeneca AZN as the latter dosed the first patient in a phase II study on T cell activating immunotherapy MEDI0457 The study will evaluate MEDI0457 in combination

Amgen's BiTE Immunotherapies Show Promise in Early Studies

Amgen Inc AMGN announced first clinical data from the early stage studies on its two investigational novel bispecific T cell engager BiTE immunotherapies AMG 420 and AMG 330 Two separate phase I studies evaluated AMG 420 which targets B cell maturation antigen BCMA and AMG 330

Global Blood Therapeutics' Voxelotor on Faster Approval Path

Global Blood Therapeutics Inc GBT announced that the FDA has agreed to its proposal of an accelerated approval pathway for its sickle cell disease SCD candidate voxelotor The company will file a new drug application NDA under this pathway The company anticipates that a rise

FDA Committee to Review Amgen's (AMGN) Osteoporosis Candidate

Amgen Inc AMGN along with European partner UCB announced that the FDA s Bone Reproductive and Urologic Drugs Advisory Committee BRUDAC will review its biologics license application BLA for Evenity romosozumab on Jan 16 2019 Amgen is looking to get Evenity approved for the treatment

Fate Therapeutics (FATE) Jumps: Stock Rises 8.9%

Fate Therapeutics Inc FATE was a big mover last session as the company saw its shares rise nearly 9 on the day The move came on solid volume too with far more shares changing hands than in a normal session This breaks the recent trend of the company as the stock is now trading above

Aileron Inks Collaboration Deal With Pfizer for Cancer Combo

Aileron Therapeutics Inc ALRN announced that it has signed a clinical trial collaboration deal with Pfizer PFE for developing a combo drug to treat amplified cancers The study will evaluate Aileron s lead candidate ALRN 6924 in combination with Pfizer s Ibrance palbociclib for

Nasdaq 100 Movers: ALXN, ADBE

In early trading on Wednesday shares of Adobe topped the list of the day s best performing components of the Nasdaq 100 index trading up 4 0 Year to date Adobe registers a 37 8 gain And the worst performing Nasdaq 100 component thus far on the day is Alexion Pharmaceuticals